0

Co-administration of Cyclosporin A and Ondansetron Decreases Transient Local Cerebral Ischemic Injury in the Mouse

Michihiro Murozono, Ryouichi Miyashita, Akiko Takeda, Kunio Ynagita, Eiichi Sato, Yukihiko Ogiwara

Neuro Endocrinol Lett. 2017 Jul;38(3):163-168.

PMID: 28759183

Abstract:

Objectives:
Several studies indicate that cyclosporin A has a protective effect against brain infarction. In this study, we aimed to determine if co-administration of cyclosporin A and ondansetron could reduce damage caused by cerebral ischemia.
Methods:
ICR (Charles River Laboratories) mice were subjected to transient focal cerebral ischemia and divided into 4 groups (O, V, C, and Mix). Immediately after reperfusion, each ligand was administered intravenously through the external jugular vein. Group V animals received 0.9% saline alone, group O animals received 0.1 mg/kg ondansetron solution, group C animals received 10 mg/kg cyclosporin A solution, and group Mix received 0.1 mg/kg ondansetron solution and 10 mg/kg cyclosporin A solution.
Results:
Our results showed that the volume of brain infarction induced by middle cerebral artery occlusion in group Mix was significantly smaller than that seen in group V. Forty-eight hours after ischemia, the neurological scores of rats from group Mix significantly improved when compared to group V.
Conclusion:
Overall, our study showed that a combination of cyclosporin A and ondansetron may be a practical clinical method to treat brain infarction. However, further studies are required to investigate the cerebroprotective mechanism of action, the possible side effects of co-administration of these drugs, and the ability of these ligands to cross the blood brain barrier.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP59865133-D Cyclosporin A solution Cyclosporin A solution 59865-13-3 Price
qrcode